ENRIGHT PATRICK G 4

Accession 0001209191-23-054904

CIK 0001907108other

Filed

Nov 8, 7:00 PM ET

Accepted

Nov 9, 8:32 PM ET

Size

19.4 KB

Accession

0001209191-23-054904

Form 4

Period: 2023-11-07

10% Owner

Transactions

Conversion
Common Stock
2023-11-07+1,793,429→ 1,793,429 total(indirect: By Longitude Venture Partners IV, L.P.)
Conversion
Common Stock
2023-11-07+319,126→ 2,112,555 total(indirect: By Longitude Venture Partners IV, L.P.)
Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,567,100 total(indirect: By Longitude Venture Partners IV, L.P.)
Conversion
Series A convertible preferred stock
2023-11-07−18,999,999→ 0 total(indirect: By Longitude Venture Partners IV, L.P.)
→ Common Stock (1,793,429 underlying)
Conversion
Series B convertible preferred stock
2023-11-07−2,906,148→ 0 total(indirect: By Longitude Venture Partners IV, L.P.)
→ Common Stock (319,126 underlying)

10% Owner

Transactions

Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,567,100 total(indirect: By Longitude Venture Partners IV, L.P.)
Conversion
Common Stock
2023-11-07+1,793,429→ 1,793,429 total(indirect: By Longitude Venture Partners IV, L.P.)
Conversion
Series B convertible preferred stock
2023-11-07−2,906,148→ 0 total(indirect: By Longitude Venture Partners IV, L.P.)
→ Common Stock (319,126 underlying)
Conversion
Common Stock
2023-11-07+319,126→ 2,112,555 total(indirect: By Longitude Venture Partners IV, L.P.)
Conversion
Series A convertible preferred stock
2023-11-07−18,999,999→ 0 total(indirect: By Longitude Venture Partners IV, L.P.)
→ Common Stock (1,793,429 underlying)

10% Owner

Transactions

Conversion
Common Stock
2023-11-07+319,126→ 2,112,555 total(indirect: By Longitude Venture Partners IV, L.P.)
Conversion
Series A convertible preferred stock
2023-11-07−18,999,999→ 0 total(indirect: By Longitude Venture Partners IV, L.P.)
→ Common Stock (1,793,429 underlying)
Conversion
Series B convertible preferred stock
2023-11-07−2,906,148→ 0 total(indirect: By Longitude Venture Partners IV, L.P.)
→ Common Stock (319,126 underlying)
Conversion
Common Stock
2023-11-07+1,793,429→ 1,793,429 total(indirect: By Longitude Venture Partners IV, L.P.)
Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,567,100 total(indirect: By Longitude Venture Partners IV, L.P.)

10% Owner

Transactions

Conversion
Series A convertible preferred stock
2023-11-07−18,999,999→ 0 total(indirect: By Longitude Venture Partners IV, L.P.)
→ Common Stock (1,793,429 underlying)
Conversion
Common Stock
2023-11-07+1,793,429→ 1,793,429 total(indirect: By Longitude Venture Partners IV, L.P.)
Conversion
Common Stock
2023-11-07+319,126→ 2,112,555 total(indirect: By Longitude Venture Partners IV, L.P.)
Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,567,100 total(indirect: By Longitude Venture Partners IV, L.P.)
Conversion
Series B convertible preferred stock
2023-11-07−2,906,148→ 0 total(indirect: By Longitude Venture Partners IV, L.P.)
→ Common Stock (319,126 underlying)

Footnotes (3)

[F1]Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
[F2]These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
[F3]Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Documents

1 file

Lexeo Therapeutics, Inc.

CIK 0001907108

Entity typeother